Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy?

Eli Lilly has joined the trillion-dollar club, and the question every long-only investor is asking is whether the run has more room. My take: yes, but the easy money is behind us.

Eli Lilly (NYSE:LLY | LLY Price Prediction) trades at $1,123.98 with a market cap of $1.002 trillion. Our 24/7 Wall St. price target for Lilly is $1,220.42 over the next 12 months, implying 8.58% upside. The recommendation is buy with high confidence at 90%.

24/7 Wall St. Price Target Summary

How Lilly Got to a Trillion, and Where Shares Sit Now

Shares are up 50.72% over the past year but down 8.61% over the past month as investors digest a scorching run. LLY sits below its 52-week high of $1,292.65 and well above the low of $707.59.

The engine remains Mounjaro and Zepbound: Q2 2026 revenue reached $22.974 billion, up 47.67% year over year, with EPS of $8.38 beating consensus by 27.27%. Mounjaro alone posted $9.94 billion (+91% YoY), and management raised full-year revenue guidance to $85 billion to $87 billion.

Bull Case for $1,381 and Higher

The bull path takes LLY to $1,381.62, a 22.92% gain. The catalysts are real. Retatrutide, Lilly’s triple-agonist, delivered what management called “unprecedented efficacy” across three Phase 3 trials, with a BLA submission planned for Q1 2027.

Foundayo, the first oral GLP-1 with no food or water restrictions, expanded to 36,000 prescribers, and the Medicare GLP-1 Bridge Program opened access for 20 million eligible Americans at $50 per month. International incretin market share of 55% and China revenue growth of 93% in constant currency show the runway is global.

What Could Go Wrong

The bear scenario takes shares to $1,045.34, a 7% decline. Realized prices fell 13% in Q2, and concentration risk is real, with the incretin franchise generating roughly $14.87 billion of the quarter’s revenue.

Acquired IPR&D charges of $2.78 billion pressured reported earnings, and insider activity leans net selling. To be fair, bulls would note the IPR&D charges reflect aggressive pipeline building (Orna, Kelonia, Ajax, Centessa) that expands the long-term shot count, and pricing declines have been more than offset by 60% volume growth.

How Lilly Compares to Novo Nordisk and Merck

Novo Nordisk (NYSE:NVO) is the only true GLP-1 peer, and the valuation gap is stark. NVO trades at a forward P/E of 14 with quarterly revenue growth of just 2.1%, versus Lilly’s 47.7%. That gap validates Lilly’s premium multiple.

Merck (NYSE:MRK) offers a diversified big-pharma contrast. Merck’s forward P/E of 16 looks cheap on paper, but quarterly earnings shrank 19.3% year over year on Keytruda patent-cliff concerns.

The peer set makes our 24/7 Wall St. price target look reasonable: Lilly deserves a premium, but not an unlimited one.

Eli Lilly Price Prediction 2026-2030

The 24/7 Wall St. price target of $1,220.42 and buy rating at 90% confidence reflect a company still executing at the top of its industry.

The tipping factor is guidance: four straight EPS beats and a raised outlook are hard to fade. I’d be a buyer here if retatrutide’s BLA stays on track for Q1 2027. I’d stay on the sidelines if realized-price declines accelerate past 13% in coming quarters.

Looking further ahead, here is where our model projects LLY could trade, assuming continued execution.

These projections assume Lilly continues executing on its GLP-1 leadership and pipeline. Significant upside could come from a clean retatrutide launch, while downside risk centers on payer pricing pressure and eventual GLP-1 competition.

Contact [email protected] for any questions or corrections.